Bioequivalency Gene Gene Therapy Immune Response 
Camargo
DECEMBER 13, 2021
Bispecific antibodies, antibody-drug conjugates, and gene therapies all have their own specific features that must be taken into account. One common characteristic for most if not all biologics is the triggering of an immune response or anti-drug antibodies.
The Pharma Data
DECEMBER 27, 2020
STP705 is a small interfering RNA (siRNA) therapy that leverages a dual-targeted inhibitory property and polypeptide nanoparticle (PNP)-enhanced delivery to knock down both TGF-beta1 and COX-2 gene expression. RESTORE-1 is a Phase II trial of an intracerebral AAV-based gene therapy for Parkinson’s disease.
Expert insights. Personalized for you.
161 
Let's personalize your content